JP2018506964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506964A5 JP2018506964A5 JP2017535814A JP2017535814A JP2018506964A5 JP 2018506964 A5 JP2018506964 A5 JP 2018506964A5 JP 2017535814 A JP2017535814 A JP 2017535814A JP 2017535814 A JP2017535814 A JP 2017535814A JP 2018506964 A5 JP2018506964 A5 JP 2018506964A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- cell
- heavy chain
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 23
- 102000040430 polynucleotide Human genes 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 210000004671 cell-free system Anatomy 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 210000003743 erythrocyte Anatomy 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000007502 anemia Diseases 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
- 102000004195 Isomerases Human genes 0.000 claims description 4
- 108090000769 Isomerases Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 3
- 206010057249 Phagocytosis Diseases 0.000 claims description 3
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 3
- 230000035931 haemagglutination Effects 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000008782 phagocytosis Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- -1 E or D Chemical class 0.000 claims description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 102000044459 human CD47 Human genes 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 101150036449 SIRPA gene Proteins 0.000 claims 1
- 238000010276 construction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098291P | 2014-12-30 | 2014-12-30 | |
| US62/098,291 | 2014-12-30 | ||
| PCT/US2015/067642 WO2016109415A1 (en) | 2014-12-30 | 2015-12-28 | Anti-cd47 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199312A Division JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506964A JP2018506964A (ja) | 2018-03-15 |
| JP2018506964A5 true JP2018506964A5 (enExample) | 2019-05-23 |
| JP6850255B2 JP6850255B2 (ja) | 2021-03-31 |
Family
ID=56284963
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535814A Expired - Fee Related JP6850255B2 (ja) | 2014-12-30 | 2015-12-28 | 抗−ｃｄ４７抗体及びその使用 |
| JP2020199312A Pending JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199312A Pending JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10870699B2 (enExample) |
| EP (1) | EP3240569A4 (enExample) |
| JP (2) | JP6850255B2 (enExample) |
| KR (1) | KR102489471B1 (enExample) |
| CN (1) | CN107530421B (enExample) |
| AU (1) | AU2015374301B2 (enExample) |
| BR (1) | BR112017014258A2 (enExample) |
| CA (1) | CA2972604C (enExample) |
| CL (1) | CL2017001736A1 (enExample) |
| CO (1) | CO2017007673A2 (enExample) |
| EA (1) | EA037654B1 (enExample) |
| EC (1) | ECSP17041865A (enExample) |
| HK (1) | HK1245154A1 (enExample) |
| MX (1) | MX391051B (enExample) |
| SG (2) | SG11201705310TA (enExample) |
| WO (1) | WO2016109415A1 (enExample) |
| ZA (1) | ZA201704467B (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1245154A1 (zh) | 2014-12-30 | 2018-08-24 | 细胞基因公司 | 抗cd47抗体及其用途 |
| RU2727165C2 (ru) * | 2015-05-04 | 2020-07-21 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| JP7120989B2 (ja) * | 2016-07-06 | 2022-08-17 | セルジーン コーポレイション | 低免疫原性を有する抗体及びその使用 |
| SG10201913263SA (en) | 2016-09-29 | 2020-03-30 | Beijing Hanmi Pharmaceutical Co Ltd | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| US20200140565A1 (en) | 2016-10-20 | 2020-05-07 | I-Mab | Novel cd47 monoclonal antibodies and uses thereof |
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| EP3538557A4 (en) * | 2016-11-08 | 2020-11-18 | Ablexis, LLC | ANTI-CD47 ANTIBODY |
| WO2018090950A1 (zh) | 2016-11-18 | 2018-05-24 | 北京韩美药品有限公司 | 抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| KR102607101B1 (ko) * | 2017-01-26 | 2023-11-29 | 제트엘아이피 홀딩 리미티드 | Cd47 항원 결합 유닛 및 그것의 사용 |
| CN110300603B (zh) * | 2017-02-14 | 2023-04-14 | 亘喜生物科技（上海）有限公司 | Cd47-car-t细胞 |
| EP3601351A1 (en) | 2017-03-27 | 2020-02-05 | Celgene Corporation | Methods and compositions for reduction of immunogenicity |
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| MX2020001309A (es) * | 2017-08-02 | 2020-08-20 | Phanes Therapeutics Inc | Anticuerpos anti-cd47 y sus usos. |
| WO2019034895A1 (en) * | 2017-08-18 | 2019-02-21 | Ultrahuman Four Limited | LIAISON AGENTS |
| KR102366853B1 (ko) * | 2017-11-10 | 2022-02-23 | 아이-맵 바이오파마 유에스 리미티드 | Cd47 항체 및 사이토카인을 포함하는 융합 단백질 |
| AR113862A1 (es) | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | Anticuerpos anti-cd47 y sus usos para tratar cáncer |
| CA3084626A1 (en) | 2017-12-04 | 2019-06-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof |
| CN111629754B (zh) * | 2018-01-24 | 2023-10-20 | 南京传奇生物科技有限公司 | 不引起显著红血细胞凝集的抗cd47抗体 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| GB201804860D0 (en) * | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| CN112566662A (zh) | 2018-06-15 | 2021-03-26 | 阿库鲁斯生物科学公司 | 针对cd47的阻断抗体及其使用方法 |
| WO2020009725A1 (en) * | 2018-07-05 | 2020-01-09 | Trican Biotechnology Co., Ltd | Human anti-cd47 antibodies and uses thereof |
| CN110872348B (zh) * | 2018-09-03 | 2021-09-03 | 长春金赛药业有限责任公司 | 人源化抗cd47单克隆抗体及其应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2019370754A1 (en) * | 2018-10-31 | 2021-02-04 | I-Mab Biopharma Us Limited | Novel CD47 antibodies and methods of using same |
| EP3936526A4 (en) * | 2019-03-06 | 2023-03-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF |
| TW202104260A (zh) | 2019-04-05 | 2021-02-01 | 美商西建公司 | 腫瘤選擇性結合ｃｄ４７之抗體之工程 |
| EP3980747A1 (en) | 2019-06-07 | 2022-04-13 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| CN112516301B (zh) * | 2019-09-17 | 2025-03-18 | 鲁南制药集团股份有限公司 | 一种cd47单克隆抗体的液体制剂及其制备方法 |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| JP7520972B2 (ja) * | 2019-10-25 | 2024-07-23 | ウーシー バイオロジクス アイルランド リミテッド | 新規抗ｃｄ４７抗体及びその使用 |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| IL295759A (en) | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| WO2021262765A1 (en) | 2020-06-22 | 2021-12-30 | The Board Of Trustees Of The Leland Stanford Junior University | Tsp-1 inhibitors for the treatment of aged, atrophied or dystrophied muscle |
| WO2022003568A1 (en) | 2020-06-30 | 2022-01-06 | Dcprime B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| CN120040592A (zh) * | 2020-07-31 | 2025-05-27 | 百奥泰生物制药股份有限公司 | Cd47抗体及其应用 |
| EP4211156A1 (en) * | 2020-09-14 | 2023-07-19 | Sutro Biopharma, Inc. | Method for large scale production of antibodies using a cell-free protein synthesis system |
| JP2023545983A (ja) | 2020-10-07 | 2023-11-01 | セルジーン コーポレイション | リンパ系悪性腫瘍状態の二重特異性抗体治療 |
| WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| JP7454044B2 (ja) * | 2020-12-23 | 2024-03-21 | グアンドン ファポン バイオファーマ インコーポレイテッド | Ｃｄ４７を標的とする抗体及びその使用 |
| JP2024503822A (ja) * | 2021-01-05 | 2024-01-29 | ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン | Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体 |
| US20250277031A1 (en) * | 2021-01-08 | 2025-09-04 | Beijing Hanmi Pharmaceutical Co., Ltd. | Antibody specifically binding to cd47 and antigen-binding fragment thereof |
| BR112023016713A2 (pt) * | 2021-02-19 | 2023-10-31 | Seoul Nat Univ R&Db Foundation | Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024005423A1 (ko) * | 2022-06-29 | 2024-01-04 | 고려대학교 산학협력단 | 인간 FCγRS 결합력이 제거된 당화 FC 변이체들 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024015653A1 (en) * | 2022-07-10 | 2024-01-18 | Mbrace Therapeutics, Inc. | Cell-free methods of recombinant antibody production |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN120390653A (zh) | 2022-12-09 | 2025-07-29 | 辉瑞大药厂 | Cd47阻断剂及抗bcma/抗cd3双特异性抗体的组合疗法 |
| TW202440151A (zh) | 2022-12-09 | 2024-10-16 | 美商輝瑞大藥廠 | Ｃｄ４７阻斷劑及抗ｃｄ２０／抗ｃｄ３雙特異性抗體組合療法 |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ， インコーポレイテッド | Ｋｒａｓ調節化合物 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| EP4774280A1 (en) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025179135A1 (en) * | 2024-02-23 | 2025-08-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer using targeted pore-forming agents |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026136515A1 (en) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Parp7 inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE440111T1 (de) | 1999-11-29 | 2009-09-15 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| EP2131860B1 (en) * | 2007-03-20 | 2013-12-18 | Eli Lilly & Company | Anti-sclerostin antibodies |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| WO2011004847A1 (ja) * | 2009-07-07 | 2011-01-13 | 一般財団法人化学及血清療法研究所 | 新規ヒト化抗ヒトα９インテグリン抗体 |
| SI2477648T1 (sl) | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
| MX2013014789A (es) * | 2011-06-16 | 2014-01-20 | Novartis Ag | Proteinas solubles para utilizarse como productos terapeuticos. |
| EP3766511A1 (en) * | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| ME03512B (me) * | 2012-02-06 | 2020-04-20 | Inhibrx Inc | Cd47 antitijela i postupci za njihovu upotrebu |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| SG10201706383XA (en) * | 2013-02-06 | 2017-09-28 | Inhibrx Lp | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| DK2986731T3 (da) * | 2013-04-19 | 2022-08-01 | Sutro Biopharma Inc | Ekspression af biologisk aktive proteiner i et bakteriecellefrit syntesesystem ved hjælp af celleekstrakter med forhøjede niveauer af exogene chaperoner |
| HK1245154A1 (zh) | 2014-12-30 | 2018-08-24 | 细胞基因公司 | 抗cd47抗体及其用途 |
| CN116425875A (zh) | 2015-09-18 | 2023-07-14 | 安驰肿瘤公司 | 治疗性cd47抗体 |
| US9650441B2 (en) | 2015-09-21 | 2017-05-16 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
-
2015
- 2015-12-28 HK HK18104961.7A patent/HK1245154A1/zh unknown
- 2015-12-28 SG SG11201705310TA patent/SG11201705310TA/en unknown
- 2015-12-28 WO PCT/US2015/067642 patent/WO2016109415A1/en not_active Ceased
- 2015-12-28 SG SG10202007176TA patent/SG10202007176TA/en unknown
- 2015-12-28 BR BR112017014258A patent/BR112017014258A2/pt not_active IP Right Cessation
- 2015-12-28 JP JP2017535814A patent/JP6850255B2/ja not_active Expired - Fee Related
- 2015-12-28 KR KR1020177021330A patent/KR102489471B1/ko active Active
- 2015-12-28 AU AU2015374301A patent/AU2015374301B2/en not_active Ceased
- 2015-12-28 CN CN201580077136.5A patent/CN107530421B/zh not_active Expired - Fee Related
- 2015-12-28 EP EP15876093.4A patent/EP3240569A4/en not_active Withdrawn
- 2015-12-28 US US15/541,003 patent/US10870699B2/en active Active
- 2015-12-28 CA CA2972604A patent/CA2972604C/en active Active
- 2015-12-28 EA EA201791485A patent/EA037654B1/ru unknown
- 2015-12-28 MX MX2017008819A patent/MX391051B/es unknown
-
2017
- 2017-06-29 CL CL2017001736A patent/CL2017001736A1/es unknown
- 2017-06-30 EC ECIEPI201741865A patent/ECSP17041865A/es unknown
- 2017-06-30 ZA ZA2017/04467A patent/ZA201704467B/en unknown
- 2017-07-28 CO CONC2017/0007673A patent/CO2017007673A2/es unknown
-
2020
- 2020-10-29 US US16/949,459 patent/US11787860B2/en active Active
- 2020-12-01 JP JP2020199312A patent/JP2021048858A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| JP2021524256A5 (enExample) | ||
| TW202608482A (zh) | 用於治療多發性骨髓瘤之方法 | |
| EP4050034A1 (en) | Cd3 binding antibodies | |
| AU2017281034A1 (en) | CD3 binding antibodies | |
| JP2013515508A5 (enExample) | ||
| JP2012526558A5 (enExample) | ||
| JP2022549172A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| US10975165B2 (en) | De-immunised anti-ERBB3 antibodies | |
| JP2013519690A5 (enExample) | ||
| JP2023517660A5 (enExample) | ||
| JP2022521956A5 (enExample) | ||
| IL301330A (en) | CD47-CD38 bispecific antibodies | |
| AU2023353699A1 (en) | Multispecific antibodies and methods of use thereof | |
| WO2014072741A1 (en) | Humanised antibody and method of production thereof | |
| CN117120478A (zh) | 一种抗原结合分子 | |
| CA3029977A1 (en) | Antibodies with low immunogenicity and uses thereof | |
| WO2025085854A1 (en) | Sirp antibodies for treatment of hemophagocytic lymphohistiocytosis | |
| JP2023500701A5 (enExample) | ||
| WO2025085857A1 (en) | Sirp antibodies for treatment of cancer | |
| CN116462764A (zh) | 靶向cd47和her2的多特异性抗体及其用途 | |
| CA3229542A1 (en) | Anti-her2 antibodies and methods of use thereof | |
| WO2025226685A1 (en) | Sirp alpha, beta, gamma antibodies for treatment of epstein–barr virus infections | |
| US20240141062A1 (en) | Cd47-cd38 bispecific antibodies |